Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 19,277

Document Document Title
WO/2015/188944A1
This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of patients having experienced tendon-related disorders and/or injuries.  
WO/2015/191827A1
A method for reducing muscle damage and/or oxidative stress in active mammals as disclosed. In one embodiment, the mammals are administered a carnitine supplement. The L-carnitine supplement may be administered without any other pharmace...  
WO/2015/190643A1
The present invention relates to a composition for promoting the differentiation of myoblasts, the composition containing butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition ...  
WO/2015/189534A1
The invention relates to the use of compounds which inhibit VAP-1 /SSAO activity for the treatment of muscular dystrophy. The invention also relates to combined preparations comprising compounds which inhibit VAP-1 /SSAO activity, and th...  
WO/2015/188942A1
This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of patients suffering from a limited range of muscle extension, in particular from ...  
WO/2015/188945A1
This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of different forms of back pain, in particular recurrent low back pain.  
WO/2015/187977A1
The present invention relates to follistatin-Fc fusion proteins that have effects in the tissue of administration (such as an injected muscle), rather than systemic effects. The Fc domain results in dimerization of the follistatin-Fc fus...  
WO/2015/186068A1
Provided herein are crystalline beta-D-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. The crystalline beta-D-nicot...  
WO/2015/186906A1
The present invention relates to: a composition for alleviating or treating a tendon or ligament disease, containing autologous and allogeneic adipose-derived mesenchymal stem cells; a preparation method therefor; and a method for treati...  
WO/2015/184528A1
The present invention relates to botulinum toxins for use in the treatment of paratonia. In particular, the present invention relates to the treatment of paratonia by local administration of a botulinum toxin to a muscle of a patient.  
WO/2015/184260A2  
WO/2015/184003A1
Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.  
WO/2015/184279A1
A method is provided for treating a Mendelian disorder of the epigenetic machinery (e.g., Kabuki syndrome) in a subject in need thereof. In particular, the method comprises administering to the subject a ketogenic composition in an amoun...  
WO/2015/177469A1
The present invention relates to chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, the invention enables improvement of muscular quality in sarcopenic mammals ...  
WO/2015/178404A1
The present invention addresses the problem of discovering a carotenoid compound exhibiting excellent water solubility. Provided is a carotenoid derivative represented by general formula (I) [in general formula (I): X represents a carbon...  
WO/2015/179125A1
Methods are disclosed for treating multiple sclerosis comprising administering an agent that reduces expression and/or activity of Allograft inflammatory factor- 1 (Aif-1) in a subject and for screening for such agents.  
WO/2015/173684A1
This invention relates to a novel crystalline form of 6-[(4R)-4-methyl-1, 1-dioxido- 1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile which is useful as a selective androgen receptor modulator (SARM), and to compositions thereof and s...  
WO/2015/172207A1
The present invention relates to methods for culturing and generation of mesodermal progenitor cells, more particularly methods to produce mesodermal progenitor cells, starting from pluripotent stem cells. The invention relates to method...  
WO/2015/173181A1
The present invention provides compounds of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compou...  
WO/2015/170683A1
The objective of the present invention is to provide: an NOX inhibitor and an NFκB inhibitor, each having excellent activity; and a prophylactic or therapeutic agent for diseases associated with NOX or NFκB, which utilizes the NOX inhi...  
WO/2015/165279A1
Provided are new polyfluoro-substituted pyrazolopyrimidine compounds or salts represented by formulae (I) to (IX), a preparation method therefor, and a method for using said compounds and a preparation thereof to treat and inhibit autoim...  
WO/2015/166887A1
 The purpose of the present invention is to provide a novel muscle atrophy inhibitor containing an ingredient that can be taken safely over an extended period of time. It was discovered that a glycoside of quercetin, which is a type of...  
WO/2015/160793A1
Provided are novel biocompatible copolymers, compositions comprising the copolymers, and methods of using the copolymers. The copolymers are non-toxic and typically have an LCST below 37°C. Compositions comprising the copolymers can be ...  
WO/2015/158740A1
The present invention relates to compositions and methods for treating myotonic dystrophy.  
WO/2015/158836A1
The invention relates to a Mangifera (Mango) Indica preparation as Sirtuin 1 activating agent for in vivo and in vitro applications. The preparation may be used to reduce the risk of developping obesity, type II diabetes, elevated blood ...  
WO/2015/158365A1
The present invention relates to compositions and methods for treating myotonic dystrophy.  
WO/2015/161255A1
Disclosed herein are methods of treating and diagnosing muscular dystrophy. In some examples, the methods include treating muscular dystrophy by administering to the subject a therapeutically effective amount of an agent that alters the ...  
WO/2015/154721A1
An isoacteoside derivative and preparation method and use thereof; the isoacteoside derivative has a structure of formula (I): R1 and R2 are independently selected from hydrogen, halogen, hydroxyl and alkoxy oxyl; R3 and R4 are independe...  
WO/2015/156498A1
The present invention relates to a pharmaceutical composition containing an Oenothera odorata extract as an active ingredient for preventing or treating muscle atrophy, a method for preparing the same, and a food composition for preventi...  
WO/2015/150966A1
There is described a food supplement composition comprising a cucumber (Cucumis sativus) extract which in particular reduces the TNF-α level. Raw cucumber extract can inhibit the production of TNF-α in human blood without causing adver...  
WO/2015/154072A1
A topical treatment composition for treating muscle cramps, muscle stiffness, muscle pain or muscle spasms. The treatment composition includes a middle (mid) chain fatty acid (MCFA). A method of making the topical treatment composition i...  
WO/2015/150337A1
The present invention relates to new kinase inhibitors, more specifically LIM Kinase inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of ...  
WO/2015/150839A1
A compound of Formula I: R1 -L1 -C(A)(A') - CH2, - L2-R2 or a pharmaceutically acceptable salt thereof, for use in medicine, for example in the treatment of a disease or condition selected from the group comprising cancer, autistic spect...  
WO/2015/148982A1
Disclosed herein are methods and compositions for alleviating side effects of statin administration, such as myopathic or myalgic side effects, short-term memory loss, abnormal liver function, glucose intolerance, hyperglycemia, increase...  
WO/2015/146929A1
Provided is a compound, or a salt thereof, that has an excellent PKC inhibitory action, and that is useful as a prophylactic or therapeutic agent for immunological diseases, inflammatory diseases, etc. A compound represented by formula (...  
WO/2015/149005A1
Methods and compositions for cell therapy using immune modulating peptides comprising a MANF family protein, or fragment thereof, as an adjuvant to improve replacement cell viability and integration. The methods and compositions can be u...  
WO/2015/135089A1
The invention relates to a method for treating a muscular dystrophy disease in a patient, said method including the administering of an effective quantity of a botanical medicine isolated from Andrographis paniculata, in combination with...  
WO/2015/137965A1
Liquids, substantially clear liquids and foodstuffs are described that contain free acid HMB. The liquids, substantially clear liquids and foodstuffs are substantially free of crude fat and may contain soluble proteins, carbohydrates, vi...  
WO/2015/137387A1
Provided are the following: a muscle enhancing drug containing, as an effective component, an amino acid composition consisting of ornithine or a salt thereof, citrulline or a salt thereof, and arginine or a salt thereof; and a compositi...  
WO/2015/137409A1
 Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 exon in the human dystrophin gene to be skipped.  
WO/2015/133627A1
 The present invention provides an agent to prevent or improve debility, the agent containing as an active ingredient isoleucine and threonine, and an agent to prevent or improve debility, the agent further containing as an active ingr...  
WO/2015/129821A1
The present invention provides a compound that has an autotaxin inhibitory effect and is represented by formula (I) (in the formula, R1, R2, R3, R4a, R4b, R5a, and R5b are as defined in the description.), a medicine that uses said compou...  
WO/2015/123750A1
Described is a transdermal ethosome composition for the treatment of pain. The transdermal ethosome composition comprises: an alcohol; a phospholipid; water; and a magnesium salt, a TRPV1 receptor agonist, or both a magnesium salt and a ...  
WO/2015/125138A1
The present invention relates to the alleviation of adverse side effects resulting from statin therapy. The present invention further relates to the use of an inhibitor of leukotriene C 4 (LTC4) mediated activity for alleviating at least...  
WO/2015/122067A1
Provided are: a citrus seed extract-containing composition with which a novel function of citrus (particularly, a citrus seed extract) can be sufficiently exhibited; a food; a drug; and a method for producing the citrus seed extract-cont...  
WO/2015/119126A1
The purpose of the present invention is to provide a novel compound having a selective JAK3-inhibiting effect and excellent oral absorption. Moreover, the purpose of the present invention is to provide a medical drug useful, on the basis...  
WO/2015/118019A1
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  
WO/2015/119249A1
Provided are a novel myogenesis accelerator, amyotrophy suppressor, medicinal composition, and TAZ activator. The myogenesis accelerator, amyotrophy suppressor, medicinal composition, and TAZ activator according to the present invention ...  
WO/2015/118365A1
The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention r...  
WO/2015/118019A9
The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X...  

Matches 101 - 150 out of 19,277